appreciate and this Thank taking We've call. you, week an time I you Ioana. to Good everyone. us afternoon, the exciting join on had
from begin on dry is just of want results of are ensure was and driver Telander, recent behalf Phase existing update several data We Roche Friday, shareholders.
Last value, notable we clear I/IIa want for minutes AMD. the reasons, but just presented the OpRegen news have points that for Genentech, XX-month and for our shared the David data trial today, to few positives Data ago, of a including OpRegen. new and many a I on major Dr. and those cover to I with to
is AMD no degenerative or that chart, is can the to assess AMD patients. you in Dry improve a a disease read currently an resolves has dry letters vision maintain eye of on spontaneously. performance of never which As terms even visual know, number in treatment standard options vision way that also these
lost a to according X of reported fact, more publication letters to after patients In patients, recent of X,XXX of similar, identical, not Telander OpRegen patients the clinical characteristics dry than on average in months. with baseline reporting those Lancet an a visual sham-treated disease acuity AMD although Dr. by trial XX
mean with X who the same inhibitor the of Patients or still XX-month complement of treatment experienced received best X letters a loss FDA-approved period. available over an time vision
publication. and Phase therefore, study, Lancet we who not comparison, the in at In on patients call those which in and patients XX already treated the OpRegen at I/IIa the XX patients somewhat blind XX focus data available XX XX are had of we patients were baseline, matches those legally X, months, the which, reported Cohort among these
patients an X.X of OpRegen gained actually those And average letters.
of on patients point. lost while acuity therapy to at anticomplement I therapy it's of no letters OpRegen This all worth letters. repeating X.X back visual cohort X this of average comparable gained think or an patients X
than experimental So was, XX the time-matched available therapy on our outcomes, if average, compare better therapy. you best these letters
gained it. patients More others OpRegen vision those while these lost importantly,
Telander. at even in that changes, those XX with also look anatomical difference coverage received areas moves you which Coupled X only of if farther of GA, OpRegen favor months. acuity thorough patients of reported X.X by further, were with an Digging letters were our gain gains in Dr. across the average visual their who of at more BCVA the
but website, repeat retinal OpRegen tissue won't that retina presentation, years evidence critical their be I his of available a of transplant even their after version degradation OpRegen-treated layers cells. have gaining retaining our entire receiving of imaging all who is X some experiencing patients RPE it of is single should a shown on these of summary of which or
did a is important patients, phenomenon While natural not course large occurs of this occur this never disease. which observation of mind in in that keep number the to this it's a in
surgeons additionally, independently observations different using techniques. significantly our reporting raw And at sites from and for these our collected is data delivery evaluating pharma multiple by accessing and multiple partner study even
Now valuable. and small the sets studies provide. that that from on early-stage information but consistency as does sets not studies, we all not data depends small aren't which of It that data large mean know are as context conclusive their they
put reason, I to worthwhile X think this into it's things perspective. For
us First, I small. is I'm data not than comparing set The the data includes mentioned more X,XXX just to complement patients.
both loss we the to So those reliable believe and relevant vision by patients context experienced for our is data. as use
in ] X XX by to and patients unavoidably also X and number a degenerative surgeons group sites rather used routes [ the a certainly using patients patients Second, an it's large at clinical different treated different as us different findings dry delivery, XX and to for on authorization, of X these reports AMD of countries condition. majority, cohort showed in that as X improvement of determine while than of marketing our encouraging data with safety efficacy a
improvement outcome. presentation eyes and XX months and at present acuity is intended this was had demonstrated now to also at and designed accomplish over a months, which week AMD visual of last the XX months. OpRegen dry replace in also Moreover, restore exactly shown X treatment as untreated kind the
be So the future at clinical incremental future. beneficial durable Lineage while great treatment, us evidence of a to continuing our is hope a it to and seems needed that and the for value of it data of stream effect gives determine the will additional
have agreement to which the ago Taking development provide into the next a positive Genentech, few we entered we We additional a as new a the significant of support for that and services week. ongoing future event just will had second topic, OpRegen. segue a this announced minutes with
Lineage be clear, be scope will that license agreement we license the not agreement, technical our supports certain and under of the existing To clinical, also of a advancement services, the OpRegen agreement providing the existing beyond program. did is manufacturing further which new this expanding renegotiate ongoing training additional
be will by fully platform, strategies. can services support technical commercial and to include as currently additional Genentech therapy related enrolling studies support cell well IIa materials and I/IIa These technology the which Lineage's manufacturing funded Phase training and activities ongoing as additional to Phase the
pipeline. an approach are their they this provides believe our important We signal a additional making time our at when decisions support about developmental for commitment partners' of difficult
noted We are taken on actions that focusing which to is assets", recently that is our view they first-in-class representatives both pipeline those supported by Specifically, stated their "high-impact and that OpRegen recent satisfies as assets. welcome prioritize Roche toward criteria. best-in-class we they have of
these today, updated the OpRegen For with program X summarize points. of view my I'll
data announced implications candidate. we for this and our benefit the lead clinical which additional product week, validating both First, offers durability of
a agreement deepen Second, which OpRegen we've understanding investigation partner, project. and the struck expand relationship this entered our into will groundbreaking with services on we further the new of valuable and
all AMD. factors concerns potentially treating a position promising We these treatment therapy continues is market current revolutionary approach safety AMD a more despite grow creating FDA-approved commercial combine believe third, to well and and to dry us of options, dry to the patient for And with informed for population. a
and areas have in cell offers in is ocular to believe we certain OpRegen antibodies AMD transplant a not and dry We compelling molecules limited ocular approach While applications additional of of over diseases, small conditions. many could may fundamental be advantages replacement to the body. opportunity advantages which science is our applied situations, the believe cell
Genentech's Only dead podcast, President with I I'll cells Ophthalmology can replace replace Product As cells." Head couldn't on again said agree cells. and and "Antibodies more. recently quote, Vice dead can't of them Global Development a
positive where We Clearly, and cell evidence have revolutionized to statement. and not significant like to that I technology. newer therapy Roche, emerging what point degenerative to impact Bayer, can pharma Vertex, from field, many major made raised is the could And look abundant indications which diseases. cell other already entities investments companies think to oncology in capital explore investors on using transplant world Astellas there's large but are this possible chronic has or from biotech support high-caliber only it there also who've a treatment
to learning curve the welcome and for therapy, entrants validation we new also that well-controlled steep the cell this scaled especially of these we're approach, comforted indicates bring form our extremely manufacturing, they and While for experience, which our affordably long. is doing by
leader we For pointing pipeline other in this medicine we our reasons, continued this of and a while branch new by growing OpRegen. success of opportunities to remain of can the advancing and believe
is or program OPCX, to for making the have most in investments Our spinal injury. spinal to of provide cell of a this the people objective cord and example program injury. our restore which of our cells, cord function The by cord, spinal transplant comprise course, pipeline replace advanced been paralyzed is,
This great attempts the is population. have cells an field, number interest use approach and importance this of of and to in SCI patient a been there stem to
undifferentiated all efforts those or cells. stem utilized mesenchymal However,
cells At cells are or and of programs Lineage, Instead, the we don't with positive destroyed same of our found those more our has those which specifically, the we any disease. identity which, transplanting aren't this to fundamental results which clinical use compartment, cells lost stem manufacturing spinal the by naturally undifferentiated case, in because the is body, match dry closely AMD the the which far cells program. and ocular in in found the yielded compartment in in way, are approach
patients having cord anyone manufacture We've our the of spinal control. of And and process in of profile, increase advantages for adjustments demonstrated cell as for control will injury. cGMP purity not therapy further in this our the program. on and data quality made product which efficacy cells cord in-house we've to alongside and has a which we of spinal and published improve data collected years as already the manufacturing, XX we're of longer a our set long We believe we aware our facility, safety who have candidate safety manufacturing at
improving patients. transplant, our soon clinical plan as to for which will And we trial in ways to receive safety cord clearance investigating the next the initiate from deliver we To point, that as a spinal and injury delivery we to we're we performance simultaneously material run system the superior FDA. is novel in to of final addition cells
are our delays. initial regulatory the workload in process. of we from explained portion only that information the review submitted us amendment already has days those But is their fact, FDA their And us We IND past And April comments believe XX. continued the end approaching received comments of causing have take heavy of requisite FDA. to. to and their we But respond submission this a typically, to few the of expectation has
continuing so for activities we to parallel, the start-up And clinical in necessary the study. are perform
target our study But we start this [indiscernible] June. If clinical quarter, site at to we our will does present, date FDA to clearance around open in information that track this on for time. we that become likely provide first believe remain
trial, There important I are to aspects you this X today. which note of want for
the the X stopping also system stopped First, designed the cell we're been require prior has been which ventilator trials delivery deliver during testing administration. Prior have to patient completed, ventilation. cells including patient's OPCX, be without trials, to of
off-the-shelf an We offer the which safety has and have feature. thawing the also to of steps cells compatible a new approach by consider keeping of do this not which cells procedure inject associated over followed proprietary formulation, via in patient preparation of our This and ventilator with favor manual thaw X-minute a counting advantage therapies, and slow the simple is an the push connected to eliminated costly needle. dose obvious handling
and That chronic time will have injury first with program the spinal is that reached point study milestone administered OPCX because patients exciting chronic injuries. most for among will patients their X plateau in recovery. this is probably most be the significant a be Thirdly, a cord the to this
a any plateaued, observe in patient significantly who patient has to happen it can this addressable we if therapy. broaden So recovery the population for functional
injury to patients. collecting safety of assessments and present any addition So investigate are we the on signals the of in performance patients among also to functional be efficacy whether the new chronic will device,
our As economics positioning developed reach internally program success. of as the to and lead ourselves and increases, know-how our our approach technology adds our as testing, we to validation clinical growing our of a retain programs are share
are investing For we to plan this which this our strategy. with pipeline partnerships, reason, continue and aligned in
we future Eterna our could is for discuss line example, with For progress, something to a call. generate making and programs the cell next good immune hypo that cell transplant be on alliance
and the to I California Reeve expand Annual Institute the SCI make An Christopher additional input and provide Symposium. comment today field. created collaborative Dana Foundation greater & to an the drive support of Medicine this was partnerships from update SCI awareness as to wanted and second efforts conference for Investor part with We on to our Regenerative
To of kind and have is its companies conference to by injury, our delighted one speakers spinal of knowledge, the we're which and present. cord this investor-facing in only confirmed the quality
molecular In addition interventions by molecules have Lineage as and small thought electrical the last year return, and from cord aims Most speakers. we companies developed in added presented the such committed are fields. issues to being of view and continuing cell event to the transplant AbbVie, who and leaders opportunities stimulation to a of we have The to already spinal provide comprehensive and injury. add BCI
June you and coming consider I us conference joining in can from will in that Diego XX weeks, it on this You expect the an for on XX. some update us and of hope San
review a Kingsley. our Chairman, dedicated wanted our words Mr. work, our pivotal a I in played to his and the Al deepest about Before company's and creative to incredibly colleagues. handing financials, journey. He this friends few passing to call countless family, out condolences of Jill add his role in go Al the was to over long-serving and
through faith we and provides intend a for lives, memory and company and day. to honor his that both the dedication his of great Al for his man in personal was every dreams and each us and inspiration charity professional this
Jill?
